scispace - formally typeset
I

Ira Pastan

Researcher at Laboratory of Molecular Biology

Publications -  1304
Citations -  113191

Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.

Papers
More filters
Journal Article

Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.

TL;DR: In vivo stability and biodistribution of four isomers of 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaaceti c acid (CHX-DTPA), a recently developed backbone-substituted derivative of DTPA, are evaluated, indicating that differences in stereochemistry can greatly influence stability of radionuclide in the chelate.
Journal ArticleDOI

A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.

TL;DR: It is demonstrated that substitution of a single phenylalanine residue at position 983 (F983) with alanine in putative transmembrane (TM) region 12 selectively affects inhibition of Pgp-mediated drug transport by both isomers of flupentixol.
Journal ArticleDOI

Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

TL;DR: The data supports the use of Gd-DTPA, as a surrogate tracer, co-infused with MR1-1 for drug distribution monitoring in patients with GBM, and indicates that MR 1-1 co- infused with Gd -DTPA via CED is safe in the long-term setting in a pre-clinical animal model.
Journal ArticleDOI

Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts

TL;DR: Monotherapy of mice with tofacitinib (the JAK inhibitor) quells Ab responses to an immunotoxin derived from the bacterial protein Pseudomonas exotoxin A, as well as to the model Ag keyhole limpet hemocyanin, preserving the potential efficacy of biological therapeutics, including those used as cancer therapeutics.
Journal ArticleDOI

An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin.

TL;DR: The mutant toxins were coupled using a thioether linkage to monoclonal antibody B3 which recognizes an antigen present in large amounts on many human cancers.